Market Overview

2018 Pipeline Insights for Hyperuricemia - ResearchAndMarkets.com

Share:

The "Hyperuricemia
- Pipeline Insight, 2018"
drug pipelines has been added to ResearchAndMarkets.com's
offering.

This report offers comprehensive insights of the pipeline (under
development) therapeutics scenario and growth prospects across
Hyperuricemia development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Scope

  • The report provides a snapshot of the pipeline development for
    Hyperuricemia
  • The report covers pipeline activity across the complete product
    development cycle i.e. clinical, pre-clinical and discovery stages for
    Hyperuricemia
  • The report provides pipeline product profiles which includes product
    description, developmental activities, licensors & collaborators and
    chemical information
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development, route of administration, and molecule
    type for Hyperuricemia
  • The report also covers the dormant and discontinued pipeline projects
    related to Hyperuricemia

Key Topics Covered

1. Report Introduction

2. Hyperuricemia Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Hyperuricemia

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Featured

  • AstraZeneca PLC
  • CymaBay Therapeutics
  • Kissei Pharmaceutical Co.
  • LG Life Sciences
  • Nippon Chemiphar Co.
  • Polaris Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • and more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/687nlz/2018_pipeline?w=4

View Comments and Join the Discussion!
 
Fastest news service for the smartest traders
$147 Free 14 day Trial